Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- NYKD.OL
- Price
- 2.24
- Stock movement up
- +0.02 (1.08%)
- Company name
- Nykode Therapeutics ASA
- Exchange
- (OL ,
- Currency
- NOK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 732.77M
- Ent value
- 624.03M
- Price/Sales
- 119.21
- Price/Book
- 4.82
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 33.92%
- 1 year return
- -83.25%
- 3 year return
- -61.84%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-15
DIVIDENDS
NYKD.OL does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 119.21 |
| Price to Book | 4.82 |
| EV to Sales | 101.52 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 326.55M |
| EPS (TTM) | -0.12 |
| FCF per share (TTM) | -0.27 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 6.15M |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -58.85M |
| Net income (TTM) | -37.91M |
| EPS (TTM) | -0.12 |
| EPS (1y forward) | -1.40 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | -957.39% |
| Profit margin (TTM) | -616.79% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 136.53M |
| Net receivables | 0.00 |
| Total current assets | 140.02M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 9.28M |
| Total assets | 179.88M |
| Accounts payable | 3.42M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 15.09M |
| Total liabilities | 27.80M |
| Shareholder's equity | 152.08M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -87.37M |
| Capital expenditures (TTM) | 1.09M |
| Free cash flow (TTM) | -88.45M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -24.93% |
| Return on Assets | -21.08% |
| Return on Invested Capital | -24.93% |
| Cash Return on Invested Capital | -58.16% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.23 |
| Daily high | 2.29 |
| Daily low | 2.22 |
| Daily Volume | 993K |
| All-time high | 83.20 |
| 1y analyst estimate | 11.50 |
| Beta | 1.31 |
| EPS (TTM) | -0.12 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 16 May 2025 |
Downside potential
Loading...
Downside potential data
| NYKD.OL | S&P500 | |
| Current price drop from All-time high | -97.30% | -12.04% |
| Highest price drop | -97.66% | -56.47% |
| Date of highest drop | 11 Mar 2025 | 9 Mar 2009 |
| Avg drop from high | -71.91% | -11.07% |
| Avg time to new high | 120 days | 12 days |
| Max time to new high | 832 days | 1805 days |
COMPANY DETAILS
Marketcap
732.77M
Marketcap category
Small-cap
Description
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for T cell vaccine development; and research agreement with Regeneron. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.
Employees
179
Website
Investor relations
-
SEC filings
CEO
Country
Norway
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
The European markets recently experienced a downturn, with the pan-European STOXX Europe 600 Index closing about 1.4% lower due to new U.S. trade tariffs impacting investor sentiment. Despite these ch...
April 3, 2025
As global markets grapple with geopolitical tensions and consumer spending concerns, investors are keeping a close eye on economic indicators and policy shifts. Amidst this backdrop, the allure of pen...
February 25, 2025
With global markets experiencing volatility amid cautious Federal Reserve commentary and political uncertainty, investors are closely monitoring opportunities that can offer potential value. In this c...
December 27, 2024
As global markets navigate the implications of the incoming Trump administration, investors are closely watching sectors influenced by potential policy shifts. In this context, penny stocks—typically ...
November 19, 2024
OSLO, Norway, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, tod...
November 6, 2024
OSLO, Norway, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, tod...
August 14, 2024
OSLO, Norway, June 20, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, tod...
June 20, 2024
OSLO, Norway, June 11, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, tod...
June 11, 2024
OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, toda...
May 14, 2024
OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, toda...
May 14, 2024
Next page